Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT04835506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04835506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 1, 2021
Completion date
September 30, 2026
Enrollment
124 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel diseases, ulcerative colitis